{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Complete or partial responses were considered responses. Response was evaluated by imaging or clinical progression. Duration of response was measured from the time measurement criteria are met for complete or partial response until the first date that recurrent or progressive disease was objectively documented.","groups":[{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 2, Dose Level 3"}],"populationDescription":"Of the 11 Stratum 2 patients (6 dose level 2, 5 dose level 3), 2 (both in dose level 3) were considered not evaluable for response. As no participants had complete or partial responses, it was not possible to calculate duration of response.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Duration of Response for Stratum 2 (DIPG) Patients","type":"SECONDARY"}